phase III clinical study
EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer
The EMA validated a Type II Variation Application for Enhertu in advanced, HER2-positive breast cancer patients after at least one HER2-targeted therapy.
Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC
The study is comparing Enhertu to standard-of-care chemotherapy plus immunotherapy as a first-line treatment for advanced NSCLC patients with HER2 mutations.
Novartis, BeiGene Ink Licensing Deal for TIGIT Inhibitor Ociperlimab
Novartis will pay BeiGene $300 million upfront for rights to develop and commercialize the agent, which BeiGene is studying with a checkpoint inhibitor in NSCLC and solid tumors.Â
Novartis' Kymriah Flops in Second-Line LBCL, Puzzling Oncologists After Yescarta, Breyanzi Successes
At ASH, researchers tried to explain why Novartis' CAR T-cell therapy failed to improve event-free survival for second-line LBCL patients whereas similar therapies succeeded.
Tibsovo, Azacitidine Combo Shows Improved Survival, Response in Newly Diagnosed IDH1-Mutant AML
Researchers at the ASH annual meeting suggested that Tibsovo-azacitidine could be a better option than Venclexta-azacitidine for chemo ineligible IDH1-mutant AML patients.